| Nov 18 |
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
|
| Nov 18 |
Aclaris Therapeutics Announces $80 Million Private Placement
|
| Nov 18 |
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
|
| Nov 12 |
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts
|
| Nov 6 |
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 6 |
Aclaris Therapeutics GAAP EPS of -$0.11 misses by $0.05, revenue of $4.35M misses by $7.5M
|
| Nov 6 |
Aclaris: Q3 Earnings Snapshot
|
| Nov 6 |
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
| Oct 24 |
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
|
| Oct 9 |
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
|
